Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.
A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and The Wales Research Ethics Committee 2 (REC 2).